A Safety and Efficacy Study of DRL-17822, a Cholesteryl Ester Transfer Protein (CETP) Inhibitor, in Patients With Abnormal Cholesterol Levels
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 176 participants.
Also called NCT01388816
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 176 participants
- Sponsor
- Dr. Reddy's Laboratories Limited, India
- Registry
-
NCT01388816
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Italy, Poland, Ukraine
- Registry status
- Completed
Technical summary
Registry record NCT01388816. Randomized; quadruple masking; primary purpose treatment. Start 2011-07 (registry gives no type); primary completion 2012-05 (actual). Results posted on 2014-04-22.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Safety and Efficacy Study of DRL-17822, a Cholesteryl Ester Transfer Protein (CETP) Inhibitor, in Patients With Abnormal Cholesterol Levels
- Condition
- Type II Hyperlipidemia
- Intervention (Drug)
- DRL-17822 or placebo
- Lead sponsor
- Dr. Reddy's Laboratories Limited, India
- Collaborator
- PharmaNet
Record details
- Record id
cardio:ct-nct01388816- Content hash
24afa218eca39e0689e69b2a4360cecba842b068d8929aafb90ff261f9cb6de1